Multi year double bottom on PFE

I have been eying Pfizer for a long entry for my buy and hold account. PFE destroys competition financially and yet remains at a much lower market cap than Lily and a few others. Yes the company was heavily propped up by the covid vaccines but they were wildly cash flow positive without the vaccines as well. This massive double bottom would play out nicely as a risk-to-reward entry on a reliable long-term company.